Patents by Inventor Willard M. Welch

Willard M. Welch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NK1 antagonists
    Patent number: 7241798
    Abstract: The invention is to compounds exhibiting neurokinin inhibitory properties, pharmaceutical compositions comprising same and methods of treatment for neurokinin-mediated conditions.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: July 10, 2007
    Assignee: Pfizer Inc.
    Inventors: Barbara E. Segelstein, Travis T. Wager, Willard M. Welch
  • Sertraline oral concentrate
    Patent number: 7067555
    Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: June 27, 2006
    Assignee: Pfizer Inc
    Inventors: Nancy J. Harper, Gautam R. Ranade, Willard M. Welch
  • 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity
    Patent number: 7009051
    Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, X and Y are defined as in the specification. Those compounds are 5HT7 partial agonists and are useful in the treatment of several disorders of the central nervous system.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: March 7, 2006
    Assignee: Pfizer Inc
    Inventors: Willard M. Welch, Vinod Parikh
  • 5-HT receptor ligands and uses thereof
    Patent number: 6995159
    Abstract: Compounds of Formula (IC) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein .
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: February 7, 2006
    Assignee: Pfizer Inc.
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr.
  • Thieno-pyrimidin-4-one AMPA antagonists
    Patent number: 6921764
    Abstract: The present invention relates to novel quinazolin-4-one derivatives of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: July 26, 2005
    Assignee: Pfizer Inc.
    Inventors: Bertrand L Chenard, Willard M Welch, Anthony R. Reinhold
  • 5-HT receptor ligands and uses thereof
    Patent number: 6894050
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: May 17, 2005
    Assignee: Pfizer Inc.
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr., Angel Guzman-Perez, Paul A. DaSilva-Jardine, Ravi S. Garigipati, Kevin K. Liu
  • 5-HT receptor ligands and uses thereof
    Patent number: 6825198
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: November 30, 2004
    Assignee: Pfizer Inc
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr.
  • Sertraline oral concentrate
    Publication number: 20040161434
    Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Type: Application
    Filed: February 3, 2004
    Publication date: August 19, 2004
    Applicant: Pfizer Inc.
    Inventors: Nancy J. Harper, Gautam R. Ranade, Willard M. Welch
  • Sertraline oral concentrate
    Patent number: 6727283
    Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Type: Grant
    Filed: October 11, 1999
    Date of Patent: April 27, 2004
    Assignee: Pfizer Inc.
    Inventors: Nancy J. Harper, Gautam R. Ranade, Willard M. Welch
  • Quinazolin-4-one ampa antagonists
    Publication number: 20040049039
    Abstract: The present invention relates to novel quinazolin-4-one derivatives of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
    Type: Application
    Filed: August 13, 2003
    Publication date: March 11, 2004
    Applicant: Pfizer Inc
    Inventors: Bertrand L. Chenard, Willard M. Welch, Anthony R. Reinhold
  • 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity
    Publication number: 20040014769
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: July 10, 2003
    Publication date: January 22, 2004
    Applicant: Pfizer Inc.
    Inventors: Willard M. Welch, Vinod Parikh
  • Quinazolin-4-one AMPA antagonists
    Patent number: 6627755
    Abstract: The present invention relates to novel quinazolin-4-one derivatives of the formula wherein A is a benzo or thieno fused aromatic ring; B is phenyl, pyridyl or pyrimidyl; X is N or CH; and Y-Z is —CH2NH— or —NHCH2—; and to pharmaceutical compositions containing such compounds, and the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: September 30, 2003
    Assignee: Pfizer INC
    Inventors: Bertrand L. Chenard, Willard M. Welch, Anthony R. Reinhold
  • 5-HT receptor ligands and uses thereof
    Publication number: 20030125334
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
    Type: Application
    Filed: June 5, 2002
    Publication date: July 3, 2003
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Angel Guzman-Perez, Paul A. DaSilva-Jardine, Ravi S. Garigipati, Kevin K. Liu
  • 5-HT receptor ligands and uses thereof
    Publication number: 20030105106
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
    Type: Application
    Filed: May 28, 2002
    Publication date: June 5, 2003
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch
  • SERTRALINE ORAL CONCENTRATE
    Publication number: 20030096868
    Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Type: Application
    Filed: October 11, 1999
    Publication date: May 22, 2003
    Inventors: NANCY J. HARPER, GAUTAM R. RANADE, WILLARD M. WELCH
  • 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
    Publication number: 20030008880
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: February 13, 2002
    Publication date: January 9, 2003
    Applicant: Pfizer Inc.
    Inventors: Willard M Welch, Vinod Parikh
  • Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
    Patent number: 6323208
    Abstract: The present invention relates to novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: November 27, 2001
    Assignee: Pfizer Inc
    Inventors: Bertrand L. Chenard, Willard M. Welch, Jr.
  • METHODS OF ADMINSTERING AN AMPA RECEPTOR ANTAGONIST TO TREAT DYSKINESIAS ASSOCIATED WITH DOPAMINE AGONIST THERAPY
    Publication number: 20010034345
    Abstract: The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal an effective amount of an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.
    Type: Application
    Filed: September 4, 1998
    Publication date: October 25, 2001
    Inventors: J.TIMOTHY GREENAMYRE, BERTRAND L. CHENARD, WILLARD M. WELCH, FRANK S. MENNITI
  • 2,3 disubstituded-4(3H)-quinazolinones
    Patent number: 6303615
    Abstract: The present invention relates to novel 2,3 disubstituted-4(3H)-quinazolinone compounds of the formula I: wherein, R1, R2 and R3 are as defined in the specification; and to the pharmaceutically acceptable salts of compounds of formula I, and to pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: October 16, 2001
    Assignee: Pfizer Inc
    Inventors: Mark L. Elliott, Willard M. Welch, Bertrand L. Chenard
  • Methods of administering CRF antagonists
    Patent number: 6200979
    Abstract: Substituted pyrrazoles of the formula wherein R1, R2, R3, X, Y, Z and A are as defined herein with reference to formula I; pyrazoles and pyzazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are defined herein with reference to formula VII; compounds of the formula wherein A, R3, R4 and R. are as defined herein with reference to formula VIII; and pyrrolopyzimidines of the formula wherein B1 R3, R4, R5 and R6 are as defined herein, with reference to formula IX, have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of a variety of stress-related disorders.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: March 13, 2001
    Inventors: Gene M. Bright, Yuhpyng L. Chen, Willard M. Welch